US 2025/0051848 A1Published application

High-accuracy prediction of colorectal cancer chemotherapy efficacy using machine learning applied to gene expression data

AssigneeGeorge Mason University

InventorsMohsin Saleet Jafri, Soukaina Amniouel

Life of this patent

Estimating the term…

Abstract

The present disclosure generally relates to gene expression profiling of tissue samples obtained from colorectal cancer patients who are candidates for chemotherapy treatment. More specifically, the disclosure provides methods based on characterization of gene expression which allow a physician to predict whether a patient is likely to respond well to treatment with a chemotherapeutic reagent.

Claims22

Dependent claims

A method for predicting the response of a colorectal cancer patient (CRC) patient to FOLFOX said method selected from the group consisting of:

(A) if the patient is at any stage of CRC
(i) determining in a sample isolated from said patient the expression levels of one or more biomarkers, or their expression product, wherein the biomarker is the transcript, or protein product, of one or more genes selected from the group consisting of:
GRP, FGF9, TRNP1, PHACTR3, KCNN4, CARM1, LTA4H, GTF2A1, TRIM3, GPN3, HELZ2, PPDPF, SERPINA1, SFR1, SH3GLB1, MPP7, AKRIC1, IGFBP1, HCAR3, F5, FRMD5, RPS23, ARHGAP5, PEG10, ALDH1A1, ACADSB, PSMA5, NTN4, MPI, GDPD1, VTI1B, ST6GAL2 and EPHB3;
and
(ii) comparing the expression levels of said one or more genes obtained in step (i) with established expression levels for responders and/or non-responders wherein similarities in the established expression levels for either responders or non-responders is indicative of whether the patient will respond to FOLFOX chemotherapy treatment;
(B) if the patient is at early stage of CRC
(i) determining in a sample isolated from said patient the expression levels of one or more biomarkers, or their expression product, wherein the biomarker is the transcript, or protein product, of one or more genes selected from the group consisting of:
PEG10, TRPM4, BEX2, TLR1, HOXA11, FZD3, TFAP2C, IGF1, GPR34, EPHB3, PRKAA2, FABP6, SGCE, NR4A1, FZD7, PFN2, MLF1, DAAM1, C2orf88, CPE, MYEF2, EDN3, DEFB1, PTPRR, HOXA10, DNAJC12, BNIP3, PHACTR3, ASPN, MFAP3L, FRMD5, LRRN1, PPBP, KRT23, GRM8, CYP2B6, CHRM3, and CKMT2 and
(ii) comparing the expression levels of said one or more genes obtained in step (i) with established expression levels for responders and/or non-responders wherein similarities in the established expression levels for either responders or non-responders is indicative of whether the patient will respond to FOLFOX chemotherapy treatment;
and
(C) if the patient is at the metastatic stage of CRC
(i) determining in a sample isolated from said patient the expression levels of one or more biomarkers, or their expression product, in a patient sample, wherein the biomarker is the transcript, or protein product, of one or more genes selected from the group consisting of:
EEF1D, HSD17B2, ADH1B, RPS10, CA2, RPS1,1 ADAMDEC1, AKR1B10, RAB3IP, DNASE1L3, C1QB, ZG16B, ZFP36L2, UCA1, CDKN1C, SLC2A10, RETNLB, CXCL5, CAB39L, PPAT, CLDN8, SCG5, BEX4, LTN1, CREB5, ITLN1, ABCA8, CCL28, FER1L4, CD177, IGF1, LPAR1, AGR2, MOGAT2, MT1H, EVI2B, GCG, CCL11, REG4, POU2AF1, ADTRP, SCNN1B HEPACAM2, PLA2G10, SAMSN1, GABRE, AXDND1, LRRC69, PPFIBP1, MUC5B, PLLP, MT1M, ANG, BMP, FAM107B, SIM2, ZG16, ABI3BP, ATP2A3, GZMA, MUC2, ST6GALNAC1, FCGBP, C2orf88, HSD17B6, USH1C S100A8, WT1, IGLJ3 BCAS1, B3GNT7, SPARCL, PLEC, CH25H, LGR5, MT1F, SLAMF7, ZNF300, FBXL6, RGS2, IL13RA2, NME7, REEP1, TACSTD2, EDNRB, NR5A2, P2RY14, RPL27A, CNTN3, PCK1, IGLV3-25, EPB41L3, LGALS2, CLCA1, RASSF10, FCGR3B, JCHAIN, IGKC, MS4A12, ASCL2, MLPH, CHGA, NT5E and SI and
(ii) comparing the expression levels of said one or more genes obtained in step (i) with established expression levels for responders and/or non-responders wherein similarities in the established expression levels for either responders or non-responders is indicative of whether the patient will respond to FOLFOX chemotherapy treatment.

11 more elements

A method for predicting the response of a colorectal cancer patient (CRC) patient to FOLFIRI said method selected from the group consisting of:

(A) if the patient is at any stage of CRC
(i) determining in a sample isolated from said patient the expression levels of one or more biomarkers, or their expression product, in a patient sample, wherein the biomarker is the transcript, or protein product, of one or more genes selected from the group consisting of:
AKAP12, SFRP2, CD36, PTGR2, PRKG1, SLIT2, FBXO32, S1PR3, DDR2, MAP1B, GLT8D2, NRP2, RNF183, AMOTL1, BOC, PI1, CLMP, MIR100HG, CAB39L, LEMD1, FNDC1, CDH11, ADAM12, and CTHRC1;
and
(ii) comparing the expression levels of said one or more genes obtained in step (i) with established expression levels for responders and/or non-responders wherein similarities in the established expression levels for either responders or non-responders is indicative of whether the patient will respond to FOLFIRI chemotherapy treatment;
(B) if the patient is at early stage of CRC
(i) determining in a sample isolated from said patient the expression levels of one or more biomarkers, or their expression product, in a patient sample, wherein the biomarker is the transcript, or protein product, of one or more genes selected from the group consisting of:
CCN4, ABCC13, AKAP12, GLT8D2, LUM, CTHRC1, FLRT3, SFRP2, COL1A2, MIR100HG, and PCDH7 and
(ii) comparing the expression levels of said one or more genes obtained in step (i) with established expression levels for responders and/or non-responders wherein similarities in the established expression levels for either responders or non-responders is indicative of whether the patient will respond to FOLFIRI chemotherapy treatment;
and
(C) if the patient is at metastatic stage of CRC
(i) determining in a sample isolated from said patient the expression levels of one or more biomarkers, or their expression product, in a patient sample, wherein the biomarker is the transcript, or protein product, of one or more genes selected from the group consisting of:
PTGR2, P115, RAB3IP, USP48, PCDHB16, DDR2, PAPPA, FXYD5, ZNF300, FBXO32, ZNF117, DNAH14, ENTPD2, GJB2, SLAM7, SFTA2, COL3A1, AMOTL1, PRMT6, SLIT2, CD109, KCNJ3, NRP2, SERPINB9, SIPR3, BTNL9, PCDH7, FNDC1, CDH11, PDE3A, BOC, GDAP1, and FBXO6 and
(ii) comparing the expression levels of said one or more genes obtained in step (i) with established expression levels for responders and/or non-responders wherein similarities in the established expression levels for either responders or non-responders is indicative of whether the patient will respond to FOLFIRI chemotherapy treatment.

11 more elements

A microarray for predicting the response of a colorectal cancer patient (CRC) patient to FOLFIRI or FOLFOX said microarray comprising one or more probes corresponding a group of biomarkers selected from the group consisting of:

(i) GRP, FGF9, TRNP1, PHACTR3, KCNN4, CARM1, LTA4H, GTF2A1, TRIM3, GPN3, HELZ2, PPDPF, SERPINA1, SFR1, SH3GLB1, MPP7, AKR1C1, IGFBP1, HCAR3, F5, FRMD5, RPS23, ARHGAP5, PEG10, ALDH1A1, ACADSB, PSMA5, NTN4, MPI, GDPD1, VTI1B, ST6GAL2 and EPHB3;
and
(ii) PEG10, TRPM4, BEX2, TLR1, HOXA11, FZD3, TFAP2C, IGF1, GPR34, EPHB3, PRKAA2, FABP6, SGCE, NR4A1, FZD7, PFN2, MLF1, DAAM1, C2orf88, CPE, MYEF2, EDN3, DEFB1, PTPRR, HOXA10, DNAJC12, BNIP3, PHACTR3, ASPN, MFAP3L, FRMD5, LRRN1, PPBP, KRT23, GRM8, CYP2B6, CHRM3, and CKMT2;
(iii) EEF1D, HSD17B2, ADH1B, RPS10, CA2, RPS1,1 ADAMDEC1, AKR1B10, RAB3IP, DNASE1L3, C1QB, ZG16B, ZFP36L2, UCA1, CDKN1C, SLC2A10, RETNLB, CXCL5, CAB39L, PPAT, CLDN8, SCG5, BEX4, LTN1, CREB5, ITLN1, ABCA8, CCL28, FER1L4, CD177, IGF1, LPAR1, AGR2, MOGAT2, MT1H, EVI2B, GCG, CCL11, REG4, POU2AF1, ADTRP, SCNN1B HEPACAM2, PLA2G10, SAMSN1, GABRE, AXDND1, LRRC69, PPFIBP1, MUC5B, PLLP, MT1M, ANG, BMP, FAM107B, SIM2, ZG16, ABI3BP, ATP2A3, GZMA, MUC2, ST6GALNAC1, FCGBP, C2orf88, HSD17B6, USH1C S100A8, WT1, IGLJ3 BCAS1, B3GNT7, SPARCL, PLEC, CH25H, LGR5, MT1F, SLAMF7, ZNF300, FBXL6, RGS2, IL13RA2, NME7, REEP1, TACSTD2, EDNRB, NR5A2, P2RY14, RPL27A, CNTN3, PCK1, IGLV3-25, EPB41L3, LGALS2, CLCA1, RASSF10, FCGR3B, JCHAIN, IGKC, MS4A12, ASCL2, MLPH, CHGA, NT5E and SI and (iv) AKAP12, SFRP2, CD36, PTGR2, PRKG1, SLIT2, FBXO32, SIPR3, DDR2, MAP1B, GLT8D2, NRP2, RNF183, AMOTL1, BOC, PI1, CLMP, MIR100HG, CAB39L, LEMD1, FNDC1, CDH11, ADAM12, and CTHRC1;
and
(iv) CCN4, ABCC13, AKAP12, GLT8D2, LUM, CTHRC1, FLRT3, SFRP2, COL1A2, MIR100HG, and PCDH7;
and
(vi) PTGR2, P115, RAB3IP, USP48, PCDHB16, DDR2, PAPPA, FXYD5, ZNF300, FBXO32, ZNF117, DNAH14, ENTPD2, GJB2, SLAM7, SFTA2, COL3A1, AMOTL1, PRMT6, SLIT2, CD109, KCNJ3, NRP2, SERPINB9, SIPR3, BTNL9, PCDH7, FNDC1, CDH11, PDE3A, BOC, GDAP1, and FBXO6.

5 more elements

A test kit for predicting the response of a colorectal cancer patient (CRC) patient to FOLFIRI or FOLFOX comprising a group of one or more probes for measuring the expression level of one or more biomarkers said biomarkers selected from the groups consisting of:

(i) GRP, FGF9, TRNP1, PHACTR3, KCNN4, CARM1, LTA4H, GTF2A1, TRIM3, GPN3, HELZ2, PPDPF, SERPINA1, SFR1, SH3GLB1, MPP7, AKR1C1, IGFBP1, HCAR3, F5, FRMD5, RPS23, ARHGAP5, PEG10, ALDH1A1, ACADSB, PSMA5, NTN4, MPI, GDPD1, VTI1B, ST6GAL2 and EPHB3;
and
(ii) PEG10, TRPM4, BEX2, TLR1, HOXA11, FZD3, TFAP2C, IGF1, GPR34, EPHB3, PRKAA2, FABP6, SGCE, NR4A1, FZD7, PFN2, MLF1, DAAM1, C2orf88, CPE, MYEF2, EDN3, DEFB1, PTPRR, HOXA10, DNAJC12, BNIP3, PHACTR3, ASPN, MFAP3L, FRMD5, LRRN1, PPBP, KRT23, GRM8, CYP2B6, CHRM3, and CKMT2;
(iii) EEF1D, HSD17B2, ADH1B, RPS10, CA2, RPS1,1 ADAMDEC1, AKR1B10, RAB3IP, DNASE1L3, C1QB, ZG16B, ZFP36L2, UCA1, CDKN1C, SLC2A10, RETNLB, CXCL5, CAB39L, PPAT, CLDN8, SCG5, BEX4, LTN1, CREB5, ITLN1, ABCA8, CCL28, FER1L4, CD177, IGF1, LPAR1, AGR2, MOGAT2, MT1H, EVI2B, GCG, CCL11, REG4, POU2AF1, ADTRP, SCNN1B HEPACAM2, PLA2G10, SAMSN1, GABRE, AXDND1, LRRC69, PPFIBP1, MUC5B, PLLP, MT1M, ANG, BMP, FAM107B, SIM2, ZG16, ABI3BP, ATP2A3, GZMA, MUC2, ST6GALNAC1, FCGBP, C2orf88, HSD17B6, USH1C S100A8, WT1, IGLJ3 BCAS1, B3GNT7, SPARCL, PLEC, CH25H, LGR5, MT1F, SLAMF7, ZNF300, FBXL6, RGS2, IL13RA2, NME7, REEP1, TACSTD2, EDNRB, NR5A2, P2RY14, RPL27A, CNTN3, PCK1, IGLV3-25, EPB41L3, LGALS2, CLCA1, RASSF10, FCGR3B, JCHAIN, IGKC, MS4A12, ASCL2, MLPH, CHGA, NT5E and SI and
(iv) AKAP12, SFRP2, CD36, PTGR2, PRKG1, SLIT2, FBXO32, SIPR3, DDR2, MAP1B, GLT8D2, NRP2, RNF183, AMOTL1, BOC, PI1, CLMP, MIR100HG, CAB39L, LEMD1, FNDC1, CDH11, ADAM12, and CTHRC1;
and
(iv) CCN4, ABCC13, AKAP12, GLT8D2, LUM, CTHRC1, FLRT3, SFRP2, COL1A2, MIR100HG, and PCDH7;
and
(vi) PTGR2, P115, RAB3IP, USP48, PCDHB16, DDR2, PAPPA, FXYD5, ZNF300, FBXO32, ZNF117, DNAH14, ENTPD2, GJB2, SLAM7, SFTA2, COL3A1, AMOTL1, PRMT6, SLIT2, CD109, KCNJ3, NRP2, SERPINB9, SIPR3, BTNL9, PCDH7, FNDC1, CDH11, PDE3A, BOC, GDAP1, and FBXO6.

6 more elements

Dependencies are inferred from the claim text.

patentgrep

Loading patent…

Abstract

A method for predicting the response of a colorectal cancer patient (CRC) patient to FOLFOX said method selected from the group consisting of:

(A) if the patient is at any stage of CRC
(i) determining in a sample isolated from said patient the expression levels of one or more biomarkers, or their expression product, wherein the biomarker is the transcript, or protein product, of one or more genes selected from the group consisting of:
GRP, FGF9, TRNP1, PHACTR3, KCNN4, CARM1, LTA4H, GTF2A1, TRIM3, GPN3, HELZ2, PPDPF, SERPINA1, SFR1, SH3GLB1, MPP7, AKRIC1, IGFBP1, HCAR3, F5, FRMD5, RPS23, ARHGAP5, PEG10, ALDH1A1, ACADSB, PSMA5, NTN4, MPI, GDPD1, VTI1B, ST6GAL2 and EPHB3;
and
(ii) comparing the expression levels of said one or more genes obtained in step (i) with established expression levels for responders and/or non-responders wherein similarities in the established expression levels for either responders or non-responders is indicative of whether the patient will respond to FOLFOX chemotherapy treatment;
(B) if the patient is at early stage of CRC
(i) determining in a sample isolated from said patient the expression levels of one or more biomarkers, or their expression product, wherein the biomarker is the transcript, or protein product, of one or more genes selected from the group consisting of:
PEG10, TRPM4, BEX2, TLR1, HOXA11, FZD3, TFAP2C, IGF1, GPR34, EPHB3, PRKAA2, FABP6, SGCE, NR4A1, FZD7, PFN2, MLF1, DAAM1, C2orf88, CPE, MYEF2, EDN3, DEFB1, PTPRR, HOXA10, DNAJC12, BNIP3, PHACTR3, ASPN, MFAP3L, FRMD5, LRRN1, PPBP, KRT23, GRM8, CYP2B6, CHRM3, and CKMT2 and
(ii) comparing the expression levels of said one or more genes obtained in step (i) with established expression levels for responders and/or non-responders wherein similarities in the established expression levels for either responders or non-responders is indicative of whether the patient will respond to FOLFOX chemotherapy treatment;
and
(C) if the patient is at the metastatic stage of CRC
(i) determining in a sample isolated from said patient the expression levels of one or more biomarkers, or their expression product, in a patient sample, wherein the biomarker is the transcript, or protein product, of one or more genes selected from the group consisting of:
EEF1D, HSD17B2, ADH1B, RPS10, CA2, RPS1,1 ADAMDEC1, AKR1B10, RAB3IP, DNASE1L3, C1QB, ZG16B, ZFP36L2, UCA1, CDKN1C, SLC2A10, RETNLB, CXCL5, CAB39L, PPAT, CLDN8, SCG5, BEX4, LTN1, CREB5, ITLN1, ABCA8, CCL28, FER1L4, CD177, IGF1, LPAR1, AGR2, MOGAT2, MT1H, EVI2B, GCG, CCL11, REG4, POU2AF1, ADTRP, SCNN1B HEPACAM2, PLA2G10, SAMSN1, GABRE, AXDND1, LRRC69, PPFIBP1, MUC5B, PLLP, MT1M, ANG, BMP, FAM107B, SIM2, ZG16, ABI3BP, ATP2A3, GZMA, MUC2, ST6GALNAC1, FCGBP, C2orf88, HSD17B6, USH1C S100A8, WT1, IGLJ3 BCAS1, B3GNT7, SPARCL, PLEC, CH25H, LGR5, MT1F, SLAMF7, ZNF300, FBXL6, RGS2, IL13RA2, NME7, REEP1, TACSTD2, EDNRB, NR5A2, P2RY14, RPL27A, CNTN3, PCK1, IGLV3-25, EPB41L3, LGALS2, CLCA1, RASSF10, FCGR3B, JCHAIN, IGKC, MS4A12, ASCL2, MLPH, CHGA, NT5E and SI and
(ii) comparing the expression levels of said one or more genes obtained in step (i) with established expression levels for responders and/or non-responders wherein similarities in the established expression levels for either responders or non-responders is indicative of whether the patient will respond to FOLFOX chemotherapy treatment.

11 more elements